论文部分内容阅读
Pulmonary artery hypertension(PAH)is a chronic progressive disease characterized by persistent elevation of pulmonary arterial vascular pressure.The disease severely limits the function of the right ventricular,causing organ failure and finally leading to death.Despite significant advances in pharmacological treatments,PAH remains an incurable disease with high morbidity and mortality.The histopathological change of PAH is featured by remodeling of the pulmonary vascular.Abnormal proliferation of pulmonary artery smooth muscle cells(PASMCs)in peripheral vascular is one major pathological finding of pulmonary vascular remodeling.Current therapeutics available for PAH primarily aim at inhibiting the pulmonary vasoconstriction and resisting pulmonary vascular remodeling.To date,only some inhibitors targeting proliferative signaling pathways have been used to suppress the proliferation of PASMCs and reverse pulmonary vascular remodeling.However,due to serious side effects their clinical use is limited and more validation is needed before the inhibitors can be transferred into clinical use.This review will focus on signal mechanisms involved in the development of PAH from a view of cell proliferation,and give an overview of recent advances in research on inhibitors targeting proliferative pathways.